Growth-inhibitory chondroitin sulfate proteoglycans (CSPG) are a primary target for
therapeutic strategies after spinal cord injury because of their contribution to the inhibitory …

Chondroitin sulphate proteoglycans (CSPGs) are potent inhibitors of growth in the adult
CNS. Use of the enzyme chondroitinase ABC (ChABC) as a strategy to reduce CSPG …

Chondroitin sulfate proteoglycans (CSPGs) are glial scar-associated molecules considered
axonal regeneration inhibitors and can be digested by chondroitinase ABC (ChABC) to …

BACKGROUND: Chondroitin sulfate proteoglycans are up-regulated in the spinal cord after
SCI, creating a molecular barrier inhibitory to axon growth. Chondroitinase ABC degrades …

After spinal cord injury (SCI), re-establishing functional circuitry in the damaged central
nervous system (CNS) faces multiple challenges including lost tissue volume, insufficient …

Chondroitin sulfate proteoglycans (CSPGs) are inhibitory extracellular matrix molecules that
are upregulated after CNS injury. Degradation of CSPGs using the enzyme chondroitinase …

Upregulation of extracellular chondroitin sulfate proteoglycans (CSPG) is a primary cause
for the failure of axons to regenerate after spinal cord injury (SCI), and the beneficial effect of …

Chondroitinase ABC (ChABC) in combination with rehabilitation has been shown to promote
functional recovery in acute spinal cord injury. For clinical use, the optimal treatment window …

Degradation of extracellular matrix chondroitin sulphate proteoglycans (CSPGs) using
Chondroitinase ABC (ChABC) is a promising strategy for the treatment of spinal cord injury …

In spinal cord injury, the injury could trigger some inhibitory signal cascades to promote
chondroitin sulfate proteoglycans (CSPGs), the structures of scar tissues, formation. CSPGs …